HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Ha Tay Pharmaceutical Joint Stock Company, known commercially as Hataphar, is one of Vietnam’s most established pharmaceutical manufacturers. Founded in 2001, the company specializes in the production and distribution of medicinal drugs, healthcare chemicals, and over-the-counter products. With more than two decades of operation, Hataphar has built a strong brand presence across Vietnam’s healthcare industry, recognized for its product quality, safety, and adherence to international pharmaceutical standards.

In 2023, Ha Tay Pharmaceutical reported total assets of USD 75.52 million and sales of USD 82.14 million, reflecting an 8.81 percent increase in revenue compared to 2022. Despite a 10.11 percent decline in profit, totaling USD 3.65 million, the company strengthened its capital structure, with equity rising 33.59 percent to USD 43.84 million. Supported by a workforce of 585 employees, Hataphar continues to expand its production capacity and market reach across Vietnam and neighboring regions.

Ha Tay Pharmaceutical Joint Stock Company is publicly listed on the Hanoi Stock Exchange (HNX) under the ticker symbol DHT. 

Key personnel 

The company is led by Chairman L.V. Lô, who oversees corporate strategy and governance. Supporting him are General Director L.X. Thắng, responsible for operations and production, and Deputy Chairman and Deputy General Director L.A. Trung, who manages business development and partnerships. Together, the leadership team has cultivated a management culture based on sustainability, innovation, and continuous improvement.

Ha Tay Pharmaceutical’s shareholder base includes both domestic and foreign investors. Aska Pharmaceutical Co., Ltd. of Japan serves as a strategic partner, bringing international expertise in pharmaceutical technology and manufacturing practices. Other key shareholders include L.V. Lô, L.V. Linh, H.V. Tuệ, and L. A Trung, representing the company’s combination of family-led management stability and external collaboration. This balanced ownership structure supports Hataphar’s continued modernization and global integration.

Financial Growth and Market Risks

Ha Tay Pharmaceutical has shown consistent financial expansion over recent years. In 2023, total assets increased by 25.09 percent, while owner’s equity grew by 33.59 percent, demonstrating strong internal financing and reinvestment capacity. Although net profit decreased due to rising input costs and competitive market conditions, the company maintained stable operations and profitability through efficient cost management and product diversification.

Operating in Vietnam’s dynamic pharmaceutical sector, Ha Tay faces challenges such as raw material price volatility, regulatory changes, and intensifying competition. However, its well-capitalized balance sheet, disciplined management, and established brand provide resilience against market pressures, ensuring sustainable long-term growth.

Business Information and RISKS

Based on current financial data and market conditions, Ha Tay Pharmaceutical Joint Stock Company is positioned for steady growth, supported by Vietnam’s expanding healthcare infrastructure and the rising demand for domestically produced medicines. The company’s strong asset base, robust equity growth, and modern manufacturing systems ensure continued competitiveness and operational stability.

What distinguishes Ha Tay Pharmaceutical is its vertically integrated business model, combining manufacturing, packaging, and distribution within a single corporate framework. The company operates advanced production facilities in Ha Noi and maintains additional branches in Ba Vi and Thuong Tin, allowing for nationwide coverage and efficient logistics. Its compliance with Good Manufacturing Practice (GMP) standards and collaboration with Aska Pharmaceutical Japan enhance its technical capacity and export readiness.

As Vietnam’s healthcare sector continues to expand, Ha Tay Pharmaceutical is well-positioned to capture new market opportunities, particularly in the prescription and OTC drug segments, while maintaining its reputation for quality and innovation.

VNBIS and Business Information Services

Vanguard Business Information LLC (VNBIS) provides a full suite of professional intelligence services designed to help investors and partners make informed business decisions when engaging with Ha Tay Pharmaceutical Joint Stock Company. These include:

• Company Credit Reports assessing financial performance, solvency, and liquidity

• Risk Management Solutions analyzes debt exposure, equity trends, and profitability risks

• Business Verification and Due Diligence Reports, ensuring transparency in ownership, governance, and compliance

Through these services, VNBIS enables clients to evaluate Ha Tay Pharmaceutical’s financial stability, operational structure, and market potential with confidence, thereby ensuring secure, data-driven business relationships.